208results about How to "Improve immune efficiency" patented technology

The invention discloses a large-scale operation workshop scheduling method based on bottleneck equipment decomposition. The large-scale operation workshop scheduling method based on the bottleneck equipment decomposition comprises the following steps of (1) acquiring data and modeling; (2) carrying out recognition on bottleneck equipment based on a key path method; (3) sorting and encoding the bottleneck equipment and non-bottleneck equipment; (4) generating an initial chromosome population; (5) carrying out cross and mutation operations on the chromosome population; (6) inoculating an immune operator to the chromosome population; (7) carrying out decoding and fitness value calculation operations on chromosomes; (8) updating an optimal chromosome and an optimal fitness value of an algorithm; (9) judging whether a method ending rule is achieved or not, starting a step (10) if the method ending rule is achieved, and otherwise, jumping to the step (5) to carry out the next iteration; (10) finding out the optimal chromosome from the step (9) to decode, and obtaining a scheduling command to schedule. According to the large-scale operation workshop scheduling method based on the bottleneck equipment decomposition, which is disclosed by the invention, a satisfactory scheduling scheme can be obtained in a shorter time, the production efficiency of an operation workshop can be improved, and the large-scale operation workshop scheduling method based on the bottleneck equipment decomposition can be applied to scheduling management and optimization of the production process of the workshop.

The invention discloses a method for producing a live swine fever vaccine by using a cell line. The present invention comprises the following technical steps: (1) selecting a cell line as the cells for making seedlings; (2) subculture and cultivation of cells for making seedlings; (3) breeding of cytotoxic species; (4) breeding of venom for making seedlings; 5) Mixing seedlings, subpackaging and freeze-drying. The invention has the advantages of simple and stable production process, easy operation, high virus content, small difference between batches, easy quality control, and can significantly improve the yield and quality of vaccines. The live swine fever vaccine produced by the invention has good safety and high immune efficacy, and has complete immune protection against the virulent attack of swine fever.

The invention discloses an avian influenza virus isolate belonging to an H9 subtype. An amino acid sequence of an HA1 structural domain of hemagglutinin has the following characteristic sites: 69-bit P, 180-bit A, 221-bit N and 236-bit R; the vaccine composition prepared by the H9 subtype avian influenza virus isolate with the following characteristic sites has good immune efficiency, and is superior to the vaccine prepared by the strain in the prior art in effect, cross protection can be provided for a popular wild strain, significant cross immunogen features are displayed, and the avian influenza virus isolate has a good application prospect in the aspect of preventing and treating poultry cross immune protection.

The invention discloses a cationic liposome, comprising cationic lipid, neutral phospholipid, polyethylene glycol derivatived phospholipid and mannose or mannan oligosaccharide, wherein a shell-shaped phospholipid bilayer is formed by phospholipid molecules in the the cationic lipid, the neutral phospholipid and the polyethylene glycol derivatived phospholipid; and mannose- or mannan oligosaccharide- modified polyethylene glycol derivatived phospholipid is formed by connecting the mannose or the mannan oligosaccharide with one end of the polyethylene glycol derivatived phospholipid. By adding the mannose- or mannan oligosaccharide- modified polyethylene glycol derivatived phospholipid, targeting property and enrichment in lymph glands of antigen-presenting cells are increased; the cationic liposome has an immunologic enhancement effect; and the immune efficacy of liposome-encapsulated vaccines can be increased. The invention also provides a preparation method of the cationic liposome.

The invention relates to a method for producing a trivalent inactivated vaccine against Haemophilus parasuis infection. The method comprises the following steps of: screening Haemophilus parasuis type 4 strain YBH04, Haemophilus parasuis type 5 strain YBH05 and Haemophilus parasuis type 13 strain YBH13 from predominant prevalence strains, which have good immunogenicity and serve as vaccine strains; inoculating to appropriate culture media for culture respectively; collecting strain suspensions; inactivating with a formaldehyde solution; adding mineral oil adjuvant; and mixing and emulsifying.The vaccine is used for preventing infection of Haemophilus parasuis type 4, Haemophilus parasuis type 5 and Haemophilus parasuis type 13 in pigs, and has the advantages of good safety, high immunization efficacy and long duration of immunity.

The invention discloses a method for preparing live vaccines of hog cholera and a product thereof. The preparation method comprises the following steps of: (1) culturing porcine passage cell lines; (2) inoculating the porcine passage cell lines with live vaccine production seed viruses of the hog cholera to obtain attenuated vaccine strains of the hog cholera; (3) performing virus multiplication on the attenuated vaccine strains of the hog cholera; (4) measuring the virus titer of multiplication virus suspension by adopting an immunofluorescence method; and (5) adding a freeze-drying protective agent and antibiotics into the virus suspension which is detected to be qualified for vaccine matching and freeze-drying. The preparation method has the advantages of producing the live vaccines of the hog cholera by using the cell lines so as to achieve small quality differences among batches and the characteristics of simple and stable process, easy operation, high yield, low cost, the feasibility and extendibility of industrial production and the like, and measuring the virus titer of the multiplication virus suspension by adopting the immunofluorescence method so as to achieve sensitive, fast, specific and accurate detection, high repeatability and reliable results. The live vaccines of the hog cholera prepared by the method can completely protect pigs from the attacks of violent hog cholera viruses.

The invention relates to a 2 type subunit vaccine for a porcine circovirus as well as a preparation method and application thereof. A recombinant bacilliform virus contains double promoters (a polyhedrin promoter and a P10 promoter), a coding gene of a Cap protein with double copying can be expressed, and the expression efficiency of the protein is obviously enhanced; moreover, the Cap protein expressed by an inserted foreign gene does not contain an excess sequence, virus-like particles (VLPs) can be effectively formed, and the immunogenicity of an expressed protein is enhanced; furthermore, a produced antigen has high content; and according to the 2 type subunit vaccine for the porcine circovirus, which is disclosed by the invention, the productivity ratio and the quality of a viral protein of the 2 type subunit vaccine for the porcine circovirus are obviously enhanced, and a prepared vaccine composition has the advantages of stable and persistent immune effect, high safety and the like.

The invention discloses a file macro virus immunization method and device. The device comprises a request intercepting and capturing module, a request analyzing module, a macro virus judging module, a first processing module and a second processing module, wherein the request intercepting and capturing module is applicable to interception and capture of a file behavior request of an Office progress; the request analyzing module is suitable for analyzing the file behavior request to obtain information of a corresponding file behavior; the macro virus judging module is suitable for judging whether a file behavior is a macro virus behavior or not; the first processing module is suitable for allowing the file behavior request when the Office progress modifies the macro virus behavior of a template file; the second processing module is suitable for stopping the file behavior request in other macro virus behaviors; the request analyzing module is suitable for analyzing parameters of an application program interface (API) to obtain information of the corresponding file behavior; and the information of the file behavior at least comprises one or more of the following information: a file path, a behavior name, a sharing manner and a file attribute. According to the file macro virus immunization method and device disclosed by the invention, an immunization range of the macro viruses can be provided and the immunization efficiency of the macro viruses is improved.

The invention provides a preparation method of carboxymethyl pachyman and a novel application of the carboxymethyl pachyman. According to the method, in the process of carrying out carboxymethylation modification on pachymaran, components and ratios of a reaction medium are changed, the reaction temperature is regulated and a catalyst process is adopted, so that the carboxymethylation efficiency of the pachymaran is remarkably improved, the utilization rate of the raw and auxiliary materials is increased, and the cost is saved. Meanwhile, by virtue of the novel application of the carboxymethyl pachyman prepared by the method to preparation of immunopotentiators of livestock and poultry, the immunity to pathogenic microorganisms of the livestock and the poultry can be remarkably enhanced, and the immune efficacy of vaccines can be improved; by virtue of the novel application of the arboxymethyl pachyman prepared by the method to feed additives, the meat performance of the livestock and the poultry can be effectively improved.

The invention discloses an automatic continuous injection unit for simultaneously injecting poultry with two drugs and belongs to the technical field of poultry syringes. The automatic continuous injection unit comprises two injection systems driven by one push system. The automatic continuous injection unit can be used for injecting two drugs simultaneously, and injection times and injection wounds are reduced for young fowls.

The invention provides a method for producing pseudorabies living vaccines by using a subculture cell source and a pseudorabies living vaccine product thereof. The method comprises the following steps: culturing pseudorabies virus low-virulent strains by using subculture cells; harvesting the strains to obtain cell culture venom; and then adding a stabilizing agent and an antibiotic into the cellculture venom, and freezing and vacuum-drying the mixture to obtain the pseudorabies living vaccines of the subculture cell source. The subculture cells are subculture cells ST of pig testicle or subculture cells PK15 or IBRS-2 of pig kidney. The method for producing the pseudorabies living vaccines by using the subculture cell source has the advantages of simple and stable production process, easy operation, high virus content, little batch difference and controllable quality, can remarkably improve the yield and quality of the vaccines and reduce the anaphylactic reaction and the like. The pseudorabies living vaccines obtained by using the production method of the invention have good safety and high immune efficacy, and have better immune protection effect on pseudorabies virulent attack.

The invention relates to a vaccine reagent kit for preventing decayed tooth, which comprises antigen and adjuvant, wherein the antigen is a dna recombinant plasmid of at least one surface proteantigen and at least one glucosyltransferase which co-express decayed tooth streptococcus mutans; and the adjuvant is flagellins of one or more than one germ. The vaccine reagent kit for preventing the decayed tooth has strong immunogenicity, can excite comprehensive and lasting immune response, and has strong specificity, even immune effect and simple and convenient operation. The invention also provides an application method for the vaccine reagent kit for preventing the decayed tooth, and the vaccine reagent kit has good immune effect and simple and convenient operation.

The invention relates to a porcine rotavirus delta VP8* subunit recombinant protein and an encoding gene of the protein. The invention further provides a recombinant protein formed after increasing tetanus toxin T cell epitope P2 into the recombinant protein, and an encoding gene. The delta VP8* protein is 64th-site to 223th-site amino acid in the VP8* and can effectively stimulate an organism to produce specific serum antibody, humoral immune response is good, the problem that the VP4 gene can not conduct prokaryotic expression due to overlarge fragment can be overcome, the protein can be expressed as a soluble protein in vitro, so that the problem that the VP8* is expressed as an inclusion body in vitro can also be overcome; the T cell epitope P2 (830th-site to 844th-site amino acid of TT) in the tetanus toxin is induced into the delta VP8* subunit recombinant protein, so that the immunity efficacy of the protein can be greatly improved, the faster and stronger neutralizing antibody titer can be induced, and high-titer rotavirus cross neutralizing antibody can also be induced.

The invention provides a method for producing a pseudorabies attenuated vaccine by using a bioreactor and a pseudorabies attenuated vaccine product. After being sterilized, the bioreactor and a micro carrier are inoculated with cells for producing the vaccine, and a cell growth medium is added for culture. A maintenance medium containing attenuated strains of pseudorabies viruses are inoculated into the bioreactor to continue culturing the cells. 2 to 3 days after virus inoculation, cell culture virus liquid is obtained and added with a stabilizer and antibiotics, and the cell culture virus liquid is refrigerated and dried under vacuum to obtain the pseudorabies attenuated vaccine. In the method, the cell density and virus concentration are improved greatly, the titer of the vaccine is improved, the side reactions, labor intensity and product cost are reduced, the monitoring performance of vaccine production is improved and uniform and stable product quality is guaranteed. The pseudorabies attenuated vaccine produced by the method has high safety, immune efficacy and good immune and protective effect against the attack by the virulent pseudorabies viruses.

The invention discloses a compound-type nano-vaccine taking an amphiphilic three-block polymer of polyethylene glycol derivative-poly lysine-poly leucine as a nano-carrier bearing a tumor antigen, an immunological adjuvant and siRNA (si Ribonucleic Acid), and a preparation method of the compound-type nano-vaccine. According to the nano-vaccine, taking and presenting of the antigen by antigen-presenting cells can be improved by a nano-micelle bearing the antigen; siRNA is efficiently delivered to TADCs (Tumor-associated Dendritic Cells) to block immunosuppression signals of TADCs, and TADCs are induced and activated by collaboration with the immunological adjuvant, so that a tumor resisting effect of a tumor vaccine is improved; the nano-vaccine has the advantages that the adopted carrier of the nano-vaccine is good in biocompatibility and low in toxicity, and is degradable in a biological body; degradation products are nontoxic and harmless, and can be absorbed or metabolized; and the preparation method of the nano-vaccine is simple and convenient and feasible, good in stability and convenient for popularization.

The invention provides a mycoplasma hyopneumoniae strain HN0613 which has better immunogenicity proved through isolation and identification, also provides a mycoplasma hyopneumoniae antigen prepared by using the mycoplasma hyopneumoniae strain HN0613 and a mycoplasma hyopneumoniae vaccine containing the mycoplasma hyopneumoniae antigen. The invention further provides a porcine circovirus type 2 / mycoplasma hyopneumoniae bicombinant vaccine, containing a PCV2 antigen (inactivated PCV2 antigen or PCV2ORF2 protein), an inactivated mycoplasma hyopneumoniae and vaccine adjuvants. Through injection of the bicombinant vaccine, the aim of preventing PCV and mycoplasma hyopneumoniae can be achieved and the effect of prevention and protection from mycoplasma hyopneumoniae infection can be achieved further.

The invention discloses a preparation method of a swine vaccine specific swine spleen transfer factor (TF). The preparation method comprises the following steps: slaughtering a swine with a positive swine vaccine antibody to harvest the swine spleen; preserving the swine spleen at low temperature; unfreezing the swine spleen; removing fasciae; mincing the swine spleen; homogenizing the pulp; filling the homogenized pulp into a bottle and storing the pulp; repeatedly freezing and thawing the pulp; centrifuging the pulp; carrying out microfiltration; carrying out ultrafiltration; carrying out inactivation; regulating the pH value; regulating the osmotic pressure; removing bacteria; and detecting the quality. The preparation method has the advantages that the pH value of water for injection is regulated to 4-6 in the pulp homogenizing step, thus being beneficial to increasing of the yields of ribose and polypeptide; a box type membrane coating is adopted for tangential flow filtration, so that the dead volumes of system residues are small and linear amplification production is easy to achieve; a 1-3KD box type membrane coating is adopted to carry out tangential flow nanofiltration on a TF crude product, thus preparing the high-concentration TF and improving the using effects; phenol red is used as an acid-base indicator, thus being convenient for clients to observe the pH value of the TF; the TF uses beta-propiolactone for inactivation instead of traditional formaldehyde and an osmotic pressure regulation process is added, thus being beneficial to combined immunization of the TF and vaccines.

The invention provides a combined live vaccine for preventing porcine reproductive and respiratory syndrome and pseudorabies, and a preparation method and application thereof. According to the invention, no immunosuppression occurs between two vaccines of the combined live vaccine; compared with each single vaccine, the combined live vaccine has no obvious difference in security, immunogenicity, immunity duration and immuno-protective effects and has remarkable immuno-protective effects on preventing porcine reproductive and respiratory syndrome and pseudorabies.

The invention relates to a vaccine adjuvant and particularly discloses a compound adjuvant for an animal vaccine. The compound adjuvant comprises raw materials in parts by weight as follows: 10-70 parts of vegetable oil for injection, 0.1-20 parts of an emulsifier, 1-10 parts of an additive, 0.01-10 parts of polymers and 0.01-5 parts of an immunopotentiator, wherein the polymers are selected from natural polymers and / or synthetic polymers. According to the animal vaccine prepared from the compound adjuvant, a synergistic effect is realized through compounding of the vegetable oil for injection, the polymers and the immunopotentiator, the immune efficacy of the animal vaccine is improved effectively, and immune protection of the animal vaccine is facilitated. Side effects of the vaccine adjuvant are reduced obviously in the aspect of animal safety compared with a mineral oil adjuvant.

The invention provides a fluid medium for culturing mycoplasma synoviae (MS), being prepared from the following components: pleuropneumonia-like organism (PPLO) broth, glucose, inactivated horse serum, yeast leachate, a phenol red solution, a coenzyme I solution and an L-cysteine solution; the pH value of the fluid medium is 7.6-7.8. The fluid medium is beneficial to the growth of the MS by supplementing various nutritional ingredients needed by microorganisms and effectively controlling the pH value of the fluid medium by sodium hydroxide; viable counts are not less than 109CCU / ml; an inactivated vaccine prepared by a bacteria solution of the MS is good in safety and immunization efficacy.

The invention relates to a serum-5 type haemophilus lus paradis vaccine strain. The classified name of the vaccine strain is haemophilus lus paradis, the strain name is JSYZ10 and the vaccine strain is preserved in the China Center for Type Culture Collection on June 15, 2014 with the preservation number of CCTCC NO:M 2014260. The invention further relates to an application of the serum-5 type haemophilus lus paradis vaccine strain in preparation of a haemophilus lus paradis inactivated vaccine. The serum-5 type haemophilus lus paradis JSYZ10 strain is stable in biology, has a strong pathogenicity to a piglet, and has a good immunogenicity when being inactivated and vaccinated on the piglet. A univalent vaccine prepared from the vaccine strain serving as a vaccine candidate strain has good safety, can produce a relatively high antibody on the piglet, has long duration and good immune potency, and can be used for resisting attack of homotype wild strains. After a pig group is immunized, the morbidity and death rate are remarkably reduced, the economic loss of a piggery is reduced, and the immunizing effect of the vaccine strain is the same as or superior to that of existing commercial vaccines on the market.

The invention relates to a method for producing avian adenovirus inactivated vaccine through an LMH clone line. The method comprises the following steps: firstly, preparation continuous cell line LMH cell; secondly, virus-seed reproduction; thirdly, virus collection, concentration and purification; fourthly, virus content determination; fifthly, inactivation and emulsification of virus, and forming emulsion inactivated vaccine. Compared with the traditional technical method for producing avian adenovirus through cell culture, the method has the advantages that high-quality inactivated vaccine with higher antigen titer through the optimization of the concentration of digestive LMH cell pancreatin-EDTA, the culture time of LMH cell and the inoculation concentration and harvest time of virus, injection immunization is performed at different doses, and all the vaccine protection rates reach 100 percent, so that the immune efficiency of the avian adenovirus type IV inactivated vaccine produced through the method is high, and the vaccine has complete immune protection effect on avian adenovirus type IV.

The invention provides a liquid medium used for culturing haemophilus parasuis. The liquid medium comprises the following components: tryptone, soya peptone, sodium chloride, dipotassium phosphate, glucose, yeast powder, bovine serum and a coenzyme I, and the liquid medium has a pH value of 7.2-7.4. The liquid medium has the beneficial effects that the liquid medium is beneficial to growth of haemophilus parasuis by supplementing the nutritional ingredients required by various microorganisms and effectively controlling the pH value in the medium via sodium hydroxide; the viable counts are not lower than 10<9>CFU / ml; and inactivated vaccines are prepared from haemophilus parasuis liquid and have good safety and immune efficacy.

The invention discloses a lateral flow immune test strip based on an ordered micro-nano structure. The lateral flow immune test strip is used for detecting a target in an analyte. According to the test strip, a base is used as a substrate, a sample pad, a conjugate pad, a chromatography pad, an ordered micro-nano structure detection pad and an absorption pad are sequentially distributed on the substrate from left to right, the sample pad is a target loading area, nanoparticles capable of being coupled with a target are combined on the conjugate pad, the ordered micro-nano structure detection pad is arranged on the chromatography pad, and a detection area and a quality control area are distributed on the ordered micro-nano structure detection pad; the sample pad and the conjugate pad are overlapped together, the conjugate pad and the chromatography pad are overlapped together, the ordered micro-nano structure detection pad is fixed on the chromatography pad, and the chromatography pad and the absorption pad are overlapped together; in practical application, when a sample reaches a detection area, multi-target detection can be realized by collecting signals; the test strip has the advantages of short detection time, simplicity and convenience in operation, low cost, simultaneous detection of multiple targets and the like, and is expected to be widely applied to the field of rapiddetection.

The invention provides thermal-stability foot-and-mouth disease O type recombinant virus as well as a preparation method and application thereof and belongs to the technical field of biological products of veterinary drugs. The virus takes an O / rV virus strain as a basic virus strain and a 98th site of structural protein VP2 is mutated into phenylalanine. According to the preparation method of therecombinant virus, point mutation S93F and point mutation Y98F are introduced into the VP2 at the same time; however, the Y98F is stably kept in a cell passage process. The FMDV O / rV-3 containing VP2Y98F has good thermal stability and a good immune effect. A thermal mutation resisting strain O / rV containing the VP2 Y98F, which is constructed by the invention, can be used as a high-quality inactivated vaccine for producing seed virus; the content of effective antigens in the inactivated vaccine is remarkably improved, the immune effect of the inactivated vaccine is increased and the inactivated vaccine is used for effectively preventing and controlling foot-and-mouth diseases of China.

The invention discloses an application of a yeast dextran injection for improving the immune efficiency of a foot-and-mouth disease vaccine of a dairy cow. Simultaneously, the invention also discloses an application of the yeast dextran injection for enhancing the cellular immune function of the dairy cow, wherein the yeast dextran injection is a 2%-6% carboxymethyl yeast dextran water solution. The yeast dextran injection prepared by the invention is safe, does not have adverse reaction, can effectively enhance the cellular immune function of the dairy cow organism and improve the antibody level of the dairy cow inoculated with an foot-and-mouth disease inactivated vaccine, and can enhance the disease resistance of animals.

The invention provides an attenuated vector bacterium of salmonella choleraesuls and a construction method of the attenuated vector bacterium and belongs to the technical field of animal bacterium genetic engineering. The attenuated vector bacterium is C78-3 salmonella choleraesuls without deltamanA, deltacrp::TT araC PBAD, deltarelA:: araC PBAD lacI TT, deltasoB and deltaasdA genes and is named as rSC0016. The method for taking a suicide vector without a resistance marker as a salmonella choleraesuls constructing vector is adopted and the utilization of the vector marked with antibiotics can be avoided; the vector can be safely used in clinical practice; furthermore, a balanced lethal system carries an exogenous antigen and can guarantee that only vaccine strains carrying the exogenous antigen can be used for producing vaccines and enter a host and survive, so that the immunity efficiency of the vaccines is improved.

The invention provides a blood serum 5 type haemophilus parasuis strain JX1002. The blood serum 5 type haemophilus parasuis strain JX1002 is collected in China Center for Type Culture Collection (CCTCC), and the collection number is CCTCC M 2014127. The strain provided by the invention is stable in biological performance, has very strong pathogenicity to piglets, and has very good immunogenicity when the strain is inoculated to the piglets after inactivation. A monovalent vaccine prepared by using the strain as a vaccine candidate strain is good in safety, can be used for generating relatively high antibodies to the piglets, is long in duration, can be used for resisting the attack of wild strains with the same type, and has very good immune efficiency. An inactivated vaccine can be used for effectively reducing the occurrence of diseases and reducing the economic loss of a pig farm in clinical use, and the immune effect of the inactivated vaccine can reach or exceed that of existing commercial vaccines in markets.